Malignant glioma: genetics and biology of a grave matter

  1. Elizabeth A. Maher1,2,
  2. Frank B. Furnari7,
  3. Robert M. Bachoo1,2,4,
  4. David H. Rowitch3,
  5. David N. Louis5,
  6. Webster K. Cavenee7,8, and
  7. Ronald A. DePinho2,6,9
  1. 1Center for Neuro-Oncology, 2Departments of Adult Oncology and 3Pediatric Oncology, Dana-Farber Cancer Institute; 4Department of Neurology, Brigham and Women's Hospital; 5Department of Pathology and Neurosurgical Service, Massachusetts General Hospital; 6Departments of Genetics and Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA; 7Ludwig Institute for Cancer Research, 8Department of Medicine, Center for Molecular Genetics, and Cancer Center, University of California–San Diego, La Jolla, California 92037, USA

This extract was created in the absence of an abstract.

Malignant brain tumors strike deep into the psyche of those receiving and those delivering the diagnosis. Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors considered to be among the deadliest of human cancers. In its most aggressive manifestation, glioblastoma (GBM), median survival ranges from 9 to 12 months, despite maximum treatment efforts—a statistical fact that has changed little over several decades of technological advances in neurosurgery, radiation therapy, and clinical trials of conventional and novel therapeutics. Over the same time period, there has been an explosion of knowledge in cancer biology and basic science discovery that has fueled meaningful progress in the treatment of many common human cancers, including those of the breast, lung, and prostate. It is perplexing that therapies used effectively in the treatment of these solid tumors are overwhelmingly ineffective in the treatment of GBM, perhaps reflecting the eccentric biology and cellular origin of this neoplasm. To date, only one new agent has been documented to have modest activity against intermediate-grade gliomas, whereas no effective agents have emerged for the treatment of GBM, despite 20 years of enrolling patients in clinical trials. It is ironic that although a comprehensive view of the genetic lesions encountered in malignant gliomas has been compiled, substantive conceptual and practical barriers remain in assigning functional significance to these genetic changes and in harnessing this basic information into the development of drugs that make a difference in patient care.

The history of treating malignant gliomas dates back to the middle of the 19th century and parallels landmark advances in modern surgical technique and the clinical discipline of neurology. The first brain tumor surgery of the modern era was performed in 1884 by Rickman Godlee (Kaye and Laws 1995). By 1900, the initial enthusiasm …

| Table of Contents

Life Science Alliance